Modality
Fusion Protein
MOA
BCL-2i
Target
Menin
Pathway
NF-κB
RSV
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
Jun 2024
→ Mar 2025
Phase 1Current
NCT05161405
2,539 pts·RSV
2024-06→2025-03·Recruiting
2,539 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-03-151.0y agoInterim· RSV
Trial Timeline
Q3Q42025
P1
Recruit…
Catalysts
Interim
2025-03-15 · 1.0y ago
RSV
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05161405 | Phase 1 | RSV | Recruiting | 2539 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |